Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) SEC filings page on Stock Titan provides structured access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases, Catalyst uses its filings to report on financial performance, material events, capital allocation decisions, and developments affecting its product portfolio, including FIRDAPSE, AGAMREE, and FYCOMPA.
Investors can review current reports on Form 8-K, where Catalyst discloses events such as quarterly financial results, authorization of share repurchase programs, patent litigation settlements related to FIRDAPSE, changes to clinical practice guidelines referencing Lambert-Eaton myasthenic syndrome and amifampridine, and updates to its Board of Directors. These filings often incorporate press releases as exhibits, providing additional context on how specific events may influence the company’s operations and CPRX stock.
In addition to event-driven 8-Ks, users can access periodic reports like Forms 10-Q and 10-K, which contain detailed discussions of product revenue, research and development spending, selling and administrative costs, and other aspects of Catalyst’s business. For a biopharmaceutical issuer, these reports are key resources for understanding revenue contributions from individual products, the status of rare disease programs, and the company’s approach to intellectual property and litigation.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy filings, helping users quickly identify items such as revenue trends, material agreements, or litigation outcomes. The platform also surfaces insider transaction reports on Form 4 when available, giving additional visibility into trading activity by officers and directors. With real-time updates from EDGAR and simplified explanations of complex regulatory documents, this CPRX filings page supports efficient, in-depth analysis of Catalyst Pharmaceuticals’ regulatory record.
Catalyst Pharmaceuticals, Inc. (CPRX)11/20/2025, he received options to purchase 34,921 shares of common stock at an exercise price of $22.77 per share, along with 10,540 restricted stock units (RSUs). The options and RSUs generally vest in three equal annual installments on November 20 of 2026, 2027, and 2028.
On 11/21/2025, 1,775 RSUs were settled, and McEnany acquired 1,775 shares of common stock, increasing his directly held common stock to 4,283,477 shares. Following these transactions, he also beneficially owned 1,881,816 derivative securities, including options and RSUs that will deliver common shares as they vest and are settled.
Catalyst Pharmaceuticals, Inc. (CPRX)947 shares of common stock, following the exercise or settlement of equity awards, bringing the director’s directly held common stock position to 7,693 shares.
The director was granted options to purchase 18,115 shares of common stock at an exercise price of
Catalyst Pharmaceuticals (CPRX) President and CEO Richard J. Daly, who also serves as a director, reported new equity awards and related share activity. On November 21, 2025, he acquired 20,006 shares of common stock through the vesting of restricted stock units and had 7,872 shares withheld to cover taxes, leaving him with 238,928 shares of common stock held directly.
On November 20, 2025, he received options to purchase 381,948 shares of common stock at an exercise price of
Catalyst Pharmaceuticals (CPRX) director reports equity awards and vesting activity. A board member filed a Form 4 disclosing equity-based compensation and related share delivery in November 2025.
The reporting person was granted options to purchase 18,115 shares of common stock at an exercise price of $22.77 on November 20, 2025. These options vest in three equal annual installments on November 20 of 2026, 2027, and 2028. The filing also shows an award of 5,468 restricted stock units (RSUs) on November 20, 2025, each convertible into one share upon vesting.
On November 21, 2025, 947 RSUs were converted, and the corresponding 947 common shares were delivered to the director. Following these transactions, the director reports beneficial ownership of 496,026 shares of Catalyst Pharmaceuticals common stock directly, along with derivative holdings consisting of options and RSUs that will deliver additional shares as they vest over time.
Catalyst Pharmaceuticals (CPRX)November 20, 2025, the officer received options to purchase 98,652 shares of common stock at an exercise price of $22.77 per share, expiring on November 20, 2032. These options vest in three equal annual installments on November 20 of 2026, 2027, and 2028.
The officer was also granted 29,776 restricted stock units (RSUs), which convert into common shares upon vesting, with the same three-year vesting schedule. On November 21, 2025, 5,161 shares underlying RSUs were delivered, while 2,030 shares were withheld to cover taxes. After these transactions, the officer directly held 234,170 shares of common stock and 969,876 derivative securities, mainly options and RSUs.
Catalyst Pharmaceuticals, Inc. (CPRX) reported insider equity activity for its Chief Commercial Officer on a Form 4. On 11/21/2025, the officer exercised 5,603 shares of common stock and had 1,641 shares withheld to cover taxes, leaving 3,962 common shares beneficially owned directly. The filing also shows a grant on 11/20/2025 of options to purchase 106,873 shares of common stock at an exercise price of $22.77, vesting in three equal annual installments on November 20, 2026, 2027 and 2028. In addition, the officer received 32,257 restricted stock units tied to common stock, and RSUs covering 5,603 shares were settled into stock on 11/21/2025. Following these transactions, the officer holds 1,064,535 derivative securities, including options and RSUs, all reported as directly owned.
Catalyst Pharmaceuticals, Inc. (CPRX) director Daniel J. Curran reported new equity awards dated 11/20/2025. He received options to purchase 18,115 shares of common stock at an exercise price of $22.77 per share, which vest in three equal annual installments on November 20, 2026, 2027 and 2028. Following this grant, he beneficially owns 58,115 stock options. He was also awarded 5,468 restricted stock units (RSUs), each representing a right to receive one share of common stock upon vesting, increasing his RSU holdings to 63,583 units. All holdings are reported as directly owned.
Catalyst Pharmaceuticals (CPRX) reported an equity award for its Chief Medical Officer on a Form 4. On November 20, 2025, the officer received options to purchase 98,652 shares of common stock at an exercise price of $22.77 per share, expiring on November 20, 2032. The grant also included 29,776 restricted stock units (RSUs), each representing one share of common stock upon vesting.
The derivative securities vest in three equal parts: one‑third on November 20, 2026, one‑third on November 20, 2027, and one‑third on November 20, 2028. After these awards, the officer beneficially owns 238,360 options and 268,136 RSUs in total, aligning compensation with the company’s long-term stock performance.
Catalyst Pharmaceuticals (CPRX) reported that it issued a press release on November 5, 2025 announcing results for the three and nine months ended September 30, 2025, along with a business update. The press release is furnished as Exhibit 99.1. This routine update signals that quarterly and year-to-date performance details are available via the attached exhibit, which also serves as the company’s formal communication of its latest operating highlights.
Catalyst Pharmaceuticals (CPRX) reported stronger Q3 2025 results. Total revenue reached $148.4 million, up from $128.7 million a year ago, driven by FIRDAPSE ($92.2 million), AGAMREE ($32.4 million), and FYCOMPA ($23.8 million). Operating income was $66.3 million and net income was $52.8 million, with diluted EPS of $0.42 versus $0.35 last year.
For the nine months, revenue rose to $436.4 million from $349.9 million, and net income increased to $161.6 million from $108.0 million. Cash and cash equivalents were $689.9 million, supported by $163.8 million in operating cash flow year-to-date. The balance sheet shows total assets of $1.05 billion, liabilities of $131.4 million, and stockholders’ equity of $920.2 million. Shares outstanding were 122,912,387 as of November 3, 2025.
FAQ
What is the current stock price of Catalyst Pharmaceuticals (CPRX)?
What is the market cap of Catalyst Pharmaceuticals (CPRX)?
